✦ LIBER ✦

Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose

✍ Scribed by M L Shiffman; C M Hofmann; V A Luketic; A J Sanyal; M J Contos; A S Mills

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 222 KB
Volume: 24
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510240105

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ribavirin exposure after the first dose

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

✍ Véronique Loustaud-Ratti; Sophie Alain; Annick Rousseau; Isabelle Fouchard Huber 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 1 views

The impact of ribavirin exposure on sustained virological response (SVR) in patients with chronic hepatitis C is unknown. Preliminary studies showed marked inter-individual variability of ribavirin concentrations despite dose adjustment for body weight (BW) and suggested there was a correlation betw

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

Response-guided peg-interferon plus riba

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future

✍ Vincent Di Martino; Carine Richou; Jean-Paul Cervoni; Jose M. Sanchez-Tapias; Do 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 1 views

Response-guided pegylated interferon (peg-IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus-infected patients provide contradictory results. We conducted meta-analyses of randomized, controlled trials to address (1) the benefit of a 72-week extended-duration thera

Severity of liver disease predicts the d

Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy

✍ Wassim Chehadeh; Widad Al-Nakib 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

## Abstract A higher prevalence of glucose abnormalities has been reported in patients with hepatitis C virus (HCV) infection compared to patients with hepatitis B virus (HBV) infection. However, previous studies considered some confounding factors and ignored others, which might influence the comp

Co-infection by serologically-silent hep

Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver

✍ Ryo Fukuda; Norihisa Ishimura; Sachiko Hamamoto; Makoto Moritani; Yasushi Uchida 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 2 views

Lymphoblastoid interferon alfa-n1 improv

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

✍ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-␣) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l